Bronchodilator reversibility in asthma and COPD: findings from three large population studies.
Administration, Inhalation
Adolescent
Adult
Aged
Aged, 80 and over
Albuterol
/ administration & dosage
Asthma
/ drug therapy
Bronchodilator Agents
/ administration & dosage
Female
Forced Expiratory Volume
Humans
Internationality
Logistic Models
Male
Middle Aged
Multivariate Analysis
Prevalence
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Spirometry
Young Adult
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
20
03
2019
accepted:
28
05
2019
pubmed:
22
6
2019
medline:
16
7
2020
entrez:
22
6
2019
Statut:
epublish
Résumé
Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and chronic obstructive pulmonary disease (COPD) and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics.Forced expiratory volume in 1 s (FEV
Identifiants
pubmed: 31221806
pii: 13993003.00561-2019
doi: 10.1183/13993003.00561-2019
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Albuterol
QF8SVZ843E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0901214
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 085790/Z/08/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: C. Janson has nothing to disclose. Conflict of interest: A. Malinovschi has nothing to disclose. Conflict of interest: A.F.S. Amaral has nothing to disclose. Conflict of interest: S. Accordini has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees and other funding from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, and other funding from Kyomed, outside the submitted work. Conflict of interest: S.A. Buist has nothing to disclose. Conflict of interest: G.W. Canonica has nothing to disclose. Conflict of interest: B. Dahlen has received personal fees from TEVA, Sanofi, GSK and AstraZeneca, outside the submitted work. Conflict of interest: J. Garcia Aymerich has nothing to disclose. Conflict of interest: L. Gnatiuc has nothing to disclose. Conflict of interest: M.L. Kowalski has nothing to disclose. Conflict of interest: J. Patel has nothing to disclose. Conflict of interest: W. Tan has nothing to disclose. Conflict of interest: K. Torén has nothing to disclose. Conflict of interest: T. Zuberbier has received consultancy fees from Bayer Health Care, FAES, Novartis and Henkel; has received grants/has grants pensing form Novartis and Henkel, and has received lecture fees from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer HealthCare, Bencradm Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, TEVA, UCB, Henkel, Kryolan and L'Oreal, outside the submitted work. Conflict of interest: P. Burney has nothing to disclose. Conflict of interest: D. Jarvis has nothing to disclose.